• Reduce text

    Reduce text
  • Restore text size

    Restore text size
  • Increase the text

    Increase the text
  • Print


Closer strategic ties between MétaGénoPolis (MGP) and BIOASTER: a broader technological offer to explore the microbiota

New impetus for research on the microbiota

Two winners of the French government’s Investments for the Future Programme (PIA), Metagenopolis-INRA (a pre-industrial demonstrator, a winner in 2012) and BIOASTER (the Technology Research Institute for Microbiology, also a winner in 2012), have declared their aim to give new impetus to research on the microbiota by signing an agreement that will enable joint, tailor-made collaborations consistent with the challenges and expectations of industry in the field of the microbiota in both humans and animals.

panel de l'offre : MGPS-BioAster
Updated on 10/04/2019
Published on 08/20/2019

A completely new technological offer

Their platforms (ISO9001/2015 accredited), designed for industry-related projects, are complementary in terms of their scientific and technological excellence, and compatible regarding their operation (timelines, standardisation of methods, management of confidentiality, etc.). They can thus provide a full range of well-structured and differentiating support with respect to the market and competition.

Joint projects with industry

Two industrial contracts are currently underway involving the two structures, focused on a variety of topics such as the identification of targets (in silico research), the screening of compounds (in vitro HTS screening) and isolation (fermenter), cultivation or evaluation (POC) in vivo.
Closer ties between the two institutes thus enable coverage of a broader technological and scientific scope regarding a complete exploration of the human and animal microbiota (see image).
Contribution of MGP to this broader offer

  • Global recognition in the field of the gut microbiota (KOL and pioneer).
  • Experts in bioanalyses, biostatistics and bioinformatics.
  • Biobank with a capacity of 600,000 stool and DNA samples.
  • Automated DNA extraction.
  • High-throughput WGS metagenomic sequencing (Ion Proton & MinION technologies): access to contrasting species and their functions.
  • Specific bioinformatics analyses and associated databases (catalogues of genes from human and animal microbiotas): identification of targets and compounds, the exploration of multi-omic data; machine learning, etc.
  • Functional metagenomics and the modulation of cell functions.

For more details: http://www.mgps.eu

Contribution of BioAster to this broader offer

  • Collection of samples from healthy volunteers for technological validations.
  • Implementation of exploratory and prospective clinical studies.
  • Targeted sequencing of 16S rNA in the V3-V4 region (Illumina MiSeq & NextSeq500 technologies).
  • Targeted sequencing of 16s rNA, full gene (proprietary LUMI-seq™ technology).
  • WGS metagenomic sequencing (Illumina MiSeq & NextSeq500 technologies).
  • Proteomic and metabolomic analyses of stool, blood and urine samples, etc., combining NMR and mass spectrometry.
  • Sorting and microfluidics methods.
  • Targeted, high-throughput culturomics of commensal bacterial species using FACS under a controlled atmosphere.
  • Exploration and development of fermentation methods for pure strains or complex microbiotas in 24-well micro-fermenters.
  • Expertise in preclinical models: wild-type and germ-free mice and those with a controlled microbiota (GM15).

For more details: https://www.bioaster.org/

Inra et Bioaster:
Karine Valeille, Inra , Vincent Thomas, Bioaster